Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates through Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products segments. The company is developing SBFM-PL4, a protease inhibitor … Read more
Sunshine Biopharma Inc (SBFM) - Net Assets
Latest net assets as of September 2025: $24.20 Million USD
Based on the latest financial reports, Sunshine Biopharma Inc (SBFM) has net assets worth $24.20 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($31.49 Million) and total liabilities ($7.29 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $24.20 Million |
| % of Total Assets | 76.85% |
| Annual Growth Rate | 55.17% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3362.21 |
Sunshine Biopharma Inc - Net Assets Trend (2007–2024)
This chart illustrates how Sunshine Biopharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sunshine Biopharma Inc (2007–2024)
The table below shows the annual net assets of Sunshine Biopharma Inc from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $23.50 Million | +10.81% |
| 2023-12-31 | $21.21 Million | -1.94% |
| 2022-12-31 | $21.63 Million | +10117.97% |
| 2021-12-31 | $211.66K | +122.17% |
| 2020-12-31 | $-954.84K | -29.84% |
| 2019-12-31 | $-735.38K | -1219.01% |
| 2018-12-31 | $-55.75K | +90.28% |
| 2017-12-31 | $-573.36K | -173.42% |
| 2016-12-31 | $-209.70K | +64.88% |
| 2015-12-31 | $-597.04K | -54.04% |
| 2014-12-31 | $-387.58K | -4926.98% |
| 2013-12-31 | $-7.71K | -110.95% |
| 2012-12-31 | $70.43K | -31.63% |
| 2011-12-31 | $103.00K | -47.51% |
| 2010-12-31 | $196.22K | +100.63% |
| 2009-12-31 | $97.80K | +652.24% |
| 2008-12-31 | $-17.71K | -232.21% |
| 2007-12-31 | $13.39K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sunshine Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6902665200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.58K | 0.01% |
| Other Comprehensive Income | $-829.96K | -3.53% |
| Other Components | $93.37 Million | 397.30% |
| Total Equity | $23.50 Million | 100.00% |
Sunshine Biopharma Inc Competitors by Market Cap
The table below lists competitors of Sunshine Biopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dien Quang JSC
VN:DQC
|
$5.06 Million |
|
FEEDBACK PLC LS-5
F:GZM0
|
$5.06 Million |
|
DILLARDS-A
BE:DL7A
|
$5.06 Million |
|
Hexagon Resources Ltd
AU:HXG
|
$5.06 Million |
|
CV Sciences Inc
OTCQB:CVSI
|
$5.05 Million |
|
SA Corporate Real Estate Fund Managers Ltd
JSE:SAC
|
$5.05 Million |
|
Peregrine Gold Ltd
AU:PGD
|
$5.05 Million |
|
Silla Sg Co. Ltd
KQ:025870
|
$5.05 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sunshine Biopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 21,207,361 to 23,500,754, a change of 2,293,393 (10.8%).
- Net loss of 5,134,000 reduced equity.
- Share repurchases of 3,139,651 reduced equity.
- New share issuances of 8,522,411 increased equity.
- Other comprehensive income decreased equity by 1,526,064.
- Other factors increased equity by 3,570,697.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.13 Million | -21.85% |
| Share Repurchases | $3.14 Million | -13.36% |
| Share Issuances | $8.52 Million | +36.26% |
| Other Comprehensive Income | $-1.53 Million | -6.49% |
| Other Changes | $3.57 Million | +15.19% |
| Total Change | $- | 10.81% |
Book Value vs Market Value Analysis
This analysis compares Sunshine Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $28.62 | $1.11 | x |
| 2008-12-31 | $-37.84 | $1.11 | x |
| 2009-12-31 | $4.17 | $1.11 | x |
| 2010-12-31 | $128.08 | $1.11 | x |
| 2011-12-31 | $42.28 | $1.11 | x |
| 2012-12-31 | $27.42 | $1.11 | x |
| 2013-12-31 | $-2.56 | $1.11 | x |
| 2014-12-31 | $-105.44 | $1.11 | x |
| 2015-12-31 | $-390.74 | $1.11 | x |
| 2016-12-31 | $-78834.59 | $1.11 | x |
| 2017-12-31 | $-13.14 | $1.11 | x |
| 2018-12-31 | $-3.66 | $1.11 | x |
| 2019-12-31 | $-416.65 | $1.11 | x |
| 2020-12-31 | $-1102.58 | $1.11 | x |
| 2021-12-31 | $162.07 | $1.11 | x |
| 2022-12-31 | $2849.48 | $1.11 | x |
| 2023-12-31 | $1743.31 | $1.11 | x |
| 2024-12-31 | $33.49 | $1.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sunshine Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.72%
- • Asset Turnover: 1.14x
- • Equity Multiplier: 1.30x
- Recent ROE (-21.85%) is above the historical average (-443.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -97.96% | 0.00% | 0.00x | 1.11x | $-14.46K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.33K |
| 2009 | -25.58% | 0.00% | 0.00x | 1.15x | $-34.80K |
| 2010 | -273.87% | 0.00% | 0.00x | 1.06x | $-557.00K |
| 2011 | -539.99% | 0.00% | 0.00x | 1.03x | $-566.50K |
| 2012 | -1005.24% | 0.00% | 0.00x | 1.91x | $-714.99K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.49 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.90 Million |
| 2015 | 0.00% | -96779.86% | 0.00x | 0.00x | $-1.59 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.48 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-982.90K |
| 2018 | 0.00% | -482.11% | 0.39x | 0.00x | $-2.15 Million |
| 2019 | 0.00% | -7860.85% | 0.22x | 0.00x | $-1.59 Million |
| 2020 | 0.00% | -3898.74% | 0.07x | 0.00x | $-2.69 Million |
| 2021 | -5875.41% | -5444.21% | 0.10x | 10.41x | $-12.46 Million |
| 2022 | -123.66% | -615.37% | 0.15x | 1.37x | $-28.91 Million |
| 2023 | -21.25% | -18.70% | 0.88x | 1.29x | $-6.63 Million |
| 2024 | -21.85% | -14.72% | 1.14x | 1.30x | $-7.48 Million |
Industry Comparison
This section compares Sunshine Biopharma Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sunshine Biopharma Inc (SBFM) | $24.20 Million | -97.96% | 0.30x | $5.06 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |